Aadi bioscience announces improved anti-tumor activity of kras inhibitors in combination with nab-sirolimus at the 34th eortc-nci-aacr symposium

Nab-sirolimus added to kras inhibitor treatment demonstrated significantly greater antitumor activity and tumor regressions compared to the kras inhibitors alone the kras inhibitor combinations with nab-sirolimus were significantly more active than the corresponding everolimus combinations los angeles , oct. 27, 2022 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today presented preclinical combination data of kras inhibitors and nab-sirolimus at the 34th eortc-nci-aacr symposium. nab-sirolimus is a novel albumin-bound nanoparticle form of the mtor inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma).
AADI Ratings Summary
AADI Quant Ranking